The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
Open Access
- 1 August 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (Supplement) , S4-S12
Abstract
Approximately 3% of US adults are immunocompromised and less capable of fighting infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be immunocompromised for reasons related to an underlying medical condition or to immunomodulatory therapies that alter the immune response. In general, vaccination with mRNA–based vaccines is effective at reducing COVID-19–associated hospitalization and death among immunocompromised populations, particularly after 3 or more doses. However, the immunocompromised population is heterogeneous, with COVID-19 vaccine-elicited immune responses and risk for severe COVID-19 existing on a continuum. Therefore, understanding the impact of vaccination and the complexity of immune responses across heterogeneous immunocompromised individuals is essential for guiding effective vaccination regimens including additional (booster) doses. In this article, we provide an overview of the immunocompromised population and the burden of disease attributable to COVID-19, while discussing key opportunities and challenges of vaccinating immunocompromised individuals.Keywords
This publication has 61 references indexed in Scilit:
- Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicityVaccine, 2021
- Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patientsCell Reports, 2021
- Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational StudyClinical Infectious Diseases, 2020
- Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational studyAIDS, 2020
- Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert CommitteeJournal of Clinical Immunology, 2020
- Prevalence of Immunosuppression Among US Adults, 2013JAMA, 2016
- Alterations in immune function with biologic therapies for autoimmune diseaseJournal of Allergy and Clinical Immunology, 2016
- Vaccination of immunocompromised patientsClinical Microbiology and Infection, 2012
- Secondary immunodeficiencies, including HIV infectionJournal of Allergy and Clinical Immunology, 2010